APP and metabolic dysfunction-associated steatotic liver disease: Consequently, the targets including Caspase-3 (CASP3), estrogen receptor 1 (ESR1), phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit α (PIK3CA), epidermal growth factor receptor (EGFR), tumor necrosis factor (TNF), and amyloidβ (A4) precursor protein (APP) played fundamental role in the treatment of NAFLD.